Tag: RSH

Respiratory ASX RSH physician telehealth remote patient management programme Australia asthma

Respiri launches telehealth and remote patient respiratory management program in Australia

Respiratory health technology company Respiri (ASX: RSH) is trialling a telehealth and remote patient management program in Australia that will also form the basis of the model for the US reimbursemen...
Respiri ASX RSH strategic advisor Dr Andrew Weekes Mark Levy UK

Respiri makes strategic appointments to facilitate UK wheezo launch

Days after obtaining Food and Drug Administration approval for sales of its wheezo device in the US, Respiri (ASX: RSH) has progressed its international expansion plans with strategic adviser appointm...
Respiri ASX RSH US FDA clearance approval wheezo App United States OTC

Respiri to sell wheezo device and technology in the United States after securing FDA approval

Wheezo device and app technology developer, Respiri (ASX: RSH) has received the greenlight from the United States Food and Drug Administration (FDA) to market and sell the technology as a class II med...
Respiri Pharmacy Catalyst wheezo in-pharmacy asthma patient ASX RSH

Respiri and Pharmacy Catalyst to begin wheezo in-pharmacy asthma patient program next month

Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and technology after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy...
Respiri Pharmacy 4 Less wheezo ASX RSH

Respiri teams up with Pharmacy 4 Less group for wheezo sales

Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for the sale of its asthma management device wheezo commenci...
Respiri Cipla wheezo ASX RSH orders demand brand partnership

Respiri orders up on growing demand for wheezo device, announces new brand partnership

Demand for Respiri’s (ASX: RSH) wheezo asthma management device has continued to grow following the platform’s recent commercial launch in Australia with sales orders increasing and a new banner partn...
Respiri wheezo Carlton Football Club game changers AFLW AFL logo

Respiri’s wheezo logo scores prime position on Carlton AFLW uniforms

Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has revealed its product logo will adorn the club’s officia...
Respiri RSH ASX costs wheezo technology Australian pharmacies manufacturing

Respiri shaves costs as wheezo technology continues to be well-received

With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins. The c...
Respiri ASX RSH wheezo launch Cipla pharmacists

Respiri ‘pleased’ with wheezo feedback from initial sales and marketing

Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it ...
Respiri ASX RSH patent application wheezo asthma management device

Respiri files new patent application for wheezo asthma management device

Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algorithm for its wheezo asthma management device. The new...
Respiri raises placement commercialise wheezo asthma device ASX RSH

Respiri raises $12.5 million to commercialise wheezo asthma device

eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end. ...
Respiri ASX RSH Entech Electronics wheezo

Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost

Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China, which is expected to “significantly improve” productio...
Respiri wheezo clinical study results ASX RSH 2020

Respiri unveils promising wheezo clinical study results

Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting ...
Respiri ASX RSH Carlton Football Club AFLW Team womens wheezo

Respiri teams up with Carlton Football Club to promote wheezo device

A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, comme...
Respiri ASX RSH Australian Patients Association APA asthma wheezo

Respiri signs referral agreement with APA to proliferate wheezo in Australia

eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the A...
Respiri ASX RSH Australian Patients Association wheezo real world study

Respiri partners with Australian Patients Association for wheezo study

eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma suff...
Respiri ASX RSH wheezo revenue 2021 Software as a Service SaaS

eHealth SaaS provider Respiri targets $6-8m revenue for 2021

eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated...
Respiri ASX RSH wheezo BNPL Zip

Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip

Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy now pay later provider Zip Co Ltd (ASX: Z1P). Respiri c...
Respiri Wheezo ASX RSH sales distribution Cipla Australia

Respiri secures global sales and distribution agreement for wheezo asthma monitoring device

Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the sales and distribution of Respiri’s wheezo asthma product...
Respiri eHealth SaaS Company Wheezo Health Data Research Hub for Respiratory Health HDR UK ASX RSH

Respiri partners with UK data research centre in preparation for Wheezo’s EU launch

eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its proprietary Wheezo devices into a new data research centre i...
Respiri ASX RSH wheezo Pharmacy Guild of Australia market potential agreement

Respiri grows wheezo market potential through agreement with the Pharmacy Guild of Australia

Respiri (ASX: RSH) has collared a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online pharmacist course on optimising asthma patient management including th...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS